At the Neurosurgery & Spine Group (NSG), based in Los Angeles, neurosurgeons Dr. Jared Ament and Dr. Amir Vokshoor have ...

A new study reveals that neural stem cell grafts can generate new myelin in the central nervous system, offering hope for ...

Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis ...

A study led by Cambridge researchers has shed light on how neural stem cell grafts could help restore myelin in the central ...

Panelists discuss the emotional and diagnostic journey of a multiple myeloma patient and his care partner, highlighting how ...

The FDA approved Lynozyfic (linvoseltamab-gcpt) to treat adults with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.

Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...

A groundbreaking NHS therapy for myeloma uses a 'Trojan horse' approach to target cancer cells, offering longer remission, ...

For patients newly diagnosed with multiple myeloma, optimal outcomes start with a clear set of goals. "The primary goals of initial treatment are straightforward: relieve symptoms like anemia ...